The therapeutic community is abuzz with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 receptor that’s demonstrating significant promise in clinical trials for managing obesity. Unlike some available weight loss treatments, retatrutide appears to deliver a greater substantial reduction in body size and benefit metabolic health,… Read More